Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions worldwide. The company’s products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors’ offices, clinical and medical research laboratories, and by patients at home under physician supervision. It manufactures products in 27 countries. Segments The company operates through two segments, BioScience and Medical Products. BioScience This segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and select vaccines. Medical Products This segment manufactures intravenous solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, intravenous nutrition products, infusion pumps, and inhalation anesthetics. This segment also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies. In addition, this segment provides products and services to treat end-stage renal disease or irreversible kidney failure. This segment manufactures solutions and other products for peritoneal dialysis, a home-based therapy, and also distributes products for hemodialysis, which is conducted in a hospital or clinic. Sales and Distribution The company has its own direct sales force and also makes sales to and through independent distributors, drug wholesalers acting as sales agents and specialty pharmacy or other alternate site providers. In the United States, Cardinal Health, Inc. warehouses and ships a portion of the company’s products through its distribution centers. International Operations The company’s international sales are made and products are distributed on a direct basis or through independent distributors or sales agents in approximately 100 countries. Its international presence includes operations in Europe, the Asia-Pacific, Latin America, and Canada. Research and Development Expenditures for the company’s research and development activities were $1.2 billion in 2012. These expenditures include costs associated with research and development activities performed at the company’s research and development centers located worldwide, which include facilities in Austria, Belgium, Japan, and the United States, as well as in-licensing, milestone, and reimbursement payments made to partners for research and development work performed at non-Baxter locations. Included in its research and development activities in 2012 were upfront payments of $113 million made during the year as the company entered into new collaboration arrangements. Significant Events In September 2013, Baxter International Inc. and Coherus Biosciences Inc. have entered into an exclusive collaboration to develop and commercialize a biosimilar to etanercept for Europe, Canada, Brazil and certain other markets. Government Regulation The Food and Drug Administration (FDA) in the United States, the European Medicines Agency in Europe, the State Food and Drug Administration in China, and other government agencies inside and outside of the United States, administer requirements covering the testing, safety, effectiveness, manufacturing, labeling, promotion and advertising, distribution and post-market surveillance of the company’s products. The company must obtain specific approval from FDA and non-U.S. regulatory authorities before it could market and sell majority of its products in a particular country. In the United States, the company is subject to the oversight of FDA, Office of the Inspector General within the Department of Health and Human Services, the Center for Medicare/Medicaid Services, the Department of Justice, Environmental Protection Agency, Department of Defense and Customs and Border Protection in addition to others. History Baxter International Inc. was founded in 1931. The company was incorporated under Delaware law in 1931.
baxter international inc (BAX*:Mexico)
One Baxter Parkway
Deerfield, IL 60015-4625
|Covidien PLC||$66.80 USD||-0.62|
|CSL Ltd||A$67.44 AUD||+0.75|
|Takeda Pharmaceutical Co Ltd||¥5,020 JPY||-50.00|
|Teva Pharmaceutical Industries Ltd||$39.51 USD||+0.15|
|View Industry Companies|
Post a JobJobs
- Pittsburgh, PA | Carnegie Museums of PittsburghPosted: Dec 09
- New York, NY | JPMorgan ChasePosted: Dec 06
- Alexandria, VA | Mack-sumner CommunicationsPosted: Dec 06
- Detroit, MI | Wayne State UniversityPosted: Nov 26
Sponsored Financial Commentaries
To contact BAXTER INTERNATIONAL INC, please visit www.baxter.com. Company data is provided by Capital IQ. Please use this form to report any data issues.